Oneness Biotech Co Ltd (4743) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Oneness Biotech Co Ltd (4743) has a cash flow conversion efficiency ratio of 0.001x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$14.32 Million ≈ $451.28K USD) by net assets (NT$10.97 Billion ≈ $345.50 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 4743 stock market capitalisation for the company's overall valuation and market capitalisation.
Oneness Biotech Co Ltd - Cash Flow Conversion Efficiency Trend (2009–2024)
This chart illustrates how Oneness Biotech Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Oneness Biotech Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oneness Biotech Co Ltd ranked by their cash flow conversion efficiency. Explore 4743 cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kunshan Top A Intelligent Equipment
SHE:300836
|
-0.017x |
|
Baida Group Co Ltd
SHG:600865
|
0.003x |
|
Phenix Optical Co Ltd
SHG:600071
|
0.083x |
|
Jai Balaji Industries Limited
NSE:JAIBALAJI
|
0.060x |
|
Center Laboratories
TWO:4123
|
0.002x |
|
Beijing Thunisoft Co Ltd
SHE:300271
|
-0.037x |
|
Daishin Sec
KO:003540
|
-0.415x |
|
Bank of Kaohsiung Ltd
TW:2836
|
-0.099x |
Annual Cash Flow Conversion Efficiency for Oneness Biotech Co Ltd (2009–2024)
The table below shows the annual cash flow conversion efficiency of Oneness Biotech Co Ltd from 2009 to 2024. View today's stock price for Oneness Biotech Co Ltd for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$12.80 Billion ≈ $403.27 Million |
NT$-345.58 Million ≈ $-10.89 Million |
-0.027x | +0.94% |
| 2023-12-31 | NT$14.50 Billion ≈ $456.74 Million |
NT$-395.13 Million ≈ $-12.45 Million |
-0.027x | +53.97% |
| 2022-12-31 | NT$14.88 Billion ≈ $468.80 Million |
NT$-881.00 Million ≈ $-27.76 Million |
-0.059x | -188.75% |
| 2021-12-31 | NT$14.09 Billion ≈ $443.89 Million |
NT$-288.89 Million ≈ $-9.10 Million |
-0.021x | -278.41% |
| 2020-12-31 | NT$13.76 Billion ≈ $433.50 Million |
NT$158.14 Million ≈ $4.98 Million |
0.011x | +134.81% |
| 2019-12-31 | NT$6.46 Billion ≈ $203.48 Million |
NT$-213.25 Million ≈ $-6.72 Million |
-0.033x | -1295.85% |
| 2018-12-31 | NT$2.17 Billion ≈ $68.23 Million |
NT$-5.12 Million ≈ $-161.40K |
-0.002x | +96.43% |
| 2017-12-31 | NT$2.49 Billion ≈ $78.60 Million |
NT$-165.27 Million ≈ $-5.21 Million |
-0.066x | -54.05% |
| 2016-12-31 | NT$2.52 Billion ≈ $79.53 Million |
NT$-108.54 Million ≈ $-3.42 Million |
-0.043x | +16.46% |
| 2015-12-31 | NT$2.77 Billion ≈ $87.13 Million |
NT$-142.34 Million ≈ $-4.48 Million |
-0.051x | +34.05% |
| 2014-12-31 | NT$1.93 Billion ≈ $60.95 Million |
NT$-150.98 Million ≈ $-4.76 Million |
-0.078x | -71.90% |
| 2013-12-31 | NT$1.97 Billion ≈ $61.94 Million |
NT$-89.26 Million ≈ $-2.81 Million |
-0.045x | -364.04% |
| 2012-12-31 | NT$1.40 Billion ≈ $44.26 Million |
NT$24.15 Million ≈ $760.95K |
0.017x | +180.32% |
| 2011-12-31 | NT$1.37 Billion ≈ $43.07 Million |
NT$-29.27 Million ≈ $-922.04K |
-0.021x | -115.21% |
| 2010-12-31 | NT$1.09 Billion ≈ $34.31 Million |
NT$153.25 Million ≈ $4.83 Million |
0.141x | +252.19% |
| 2009-12-31 | NT$1.11 Billion ≈ $34.86 Million |
NT$-102.30 Million ≈ $-3.22 Million |
-0.092x | -- |
About Oneness Biotech Co Ltd
Oneness Biotech Co., Ltd. engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan. It offers Fespixon cream for diabetic foot ulcers, and Bonvadis, an innovative wound care medical device. The company develops ON101, which is in Phase III clinical trials for treating chronic diabetic foot ulcers. It is also developing FB825, which is in Phase II… Read more